Daily Management Review

Pfizer Lowers Its Top Profit Margin Following The Third Quarter’s Earnings


11/04/2016


The “average analyst” forecast of Pfizer’s earnings were missed by one percent per share.



The largest manufacturer of drugs in the U.S., Pfizer Inc., issued its “quarterly adjusted profit” which just fell a little short on standing up to the estimates of the analysts, while four cents were shaved off by the company from its “2016 earnings forecast” following the decision of putting an end to the plans of developing “cholesterol-lowering treatment”.
 
Putting aside the “special items”, Pfizer’s third quarter’s earning equals to sixty one percent per share, whereby the estimates made by the “average analyst” was missed by one percent, reports “Thomson Reuters I/B/E/S”. Ibrance is a treatment for breast cancer developed by Pfizer which brought in sale’s revenue of “$550 million”. However, it missed the “$576 million” forecast of consensus which was compiled by “Evercore ISI”.
 
On the other hand, the pain drug, Lyrica, generated sales amount of “$1.05 billion”, which too failed to meet the expectation of “$1.28 billion”, whereas the sale of “Prevnar vaccine” over shot the forecast of “$1.48 billion” and brought in “$1.54 billion”. Furthermore, Pfizer reported that it will abandon the development of “bococizumab”, a drug for lowering cholesterol, reason being cited as an “evolving treatment landscape”.
 
As a result, Pfizer brought down the top earning forecast margin of 2016 to “$2.43”, while it maintained the “lower end at $2.38”. Moreover, the company increased its “revenue forecast” from “$51 billion” to “$52 billion”, yet retained the upper limit at “$53 billion”. According to Reuters:
“Bococizumab, which belongs to a pricey new class of medicines called PCSK9 inhibitors, was always going to be late to the party, since two rival drugs hit the market last summer - Praluent, co-developed by Regeneron (REGN.O) and Sanofi SA (SASY.PA) and Repatha from Amgen Inc (AMGN.O)”.
 
 
 
 
References:
http://www.reuters.com/







Science & Technology

Germany Introduces The First Ever Train To Run On 100% Hydrogen

Germany Plans On Cyber Security Research To End Reliance On U.S. Tech

Fuchsia will kill Android by 2023: Top 5 facts about the new OS

New Study Finds Goats Interact More With Happy People

More than 32 thousand "smart" houses under threat of hacker attack

Internet addiction and children: Global plague

Apple takes up to develop Apple Watch for health monitoring

Hyperloop is growing in Europe

Analysts: US gamers prefer mobile games

Google Assistant Winner Of Head-To-Head Test Of Digital Assistants, Beats Siri And Alexa

World Politics

World & Politics

Ex-Brexit Minister Said A ‘Reset’ Is Needed For Brexit Talks

10 countries with the best healthcare systems

Foreign Experts To Be Allowed By North Korea For Permanent Destruction Of Missile Sites

Ireland recovers €14.3 billion from Apple

Is China going to cancel its birth limit policy?

The US is ready to start negotiations with China

US and China start 5G race

Is Czech Republic posing a threat to the European Union?